Headlines about PRA Health Sciences (NASDAQ:PRAH) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. PRA Health Sciences earned a coverage optimism score of 0.11 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.8663122675367 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
PRAH has been the topic of several recent analyst reports. Credit Suisse Group reaffirmed an “outperform” rating and set a $104.00 target price (up from $101.00) on shares of PRA Health Sciences in a research report on Thursday, February 22nd. KeyCorp reaffirmed a “buy” rating and set a $100.00 target price on shares of PRA Health Sciences in a research report on Wednesday, January 31st. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research report on Wednesday, January 17th. Mizuho set a $87.00 price target on PRA Health Sciences and gave the company a “buy” rating in a research note on Friday, December 1st. Finally, BidaskClub upgraded PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. PRA Health Sciences has a consensus rating of “Buy” and an average price target of $95.67.
Shares of PRA Health Sciences (NASDAQ PRAH) traded down $1.15 on Wednesday, hitting $91.02. The stock had a trading volume of 118,797 shares, compared to its average volume of 444,437. The stock has a market capitalization of $5,923.63, a P/E ratio of 69.83, a price-to-earnings-growth ratio of 1.46 and a beta of 0.46. PRA Health Sciences has a 1 year low of $58.08 and a 1 year high of $95.90. The company has a quick ratio of 0.90, a current ratio of 0.90 and a debt-to-equity ratio of 1.31.
PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.02. The company had revenue of $568.80 million during the quarter, compared to analysts’ expectations of $543.78 million. PRA Health Sciences had a return on equity of 22.77% and a net margin of 3.85%. PRA Health Sciences’s quarterly revenue was up 37.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.71 EPS. equities research analysts expect that PRA Health Sciences will post 3.81 EPS for the current fiscal year.
In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of the stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total transaction of $6,616,965.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Linda Baddour sold 67,000 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $90.27, for a total value of $6,048,090.00. The disclosure for this sale can be found here. Insiders sold a total of 212,700 shares of company stock valued at $19,282,021 in the last ninety days. 2.10% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect PRA Health Sciences (NASDAQ:PRAH) Share Price” was first published by Equities Focus and is the property of of Equities Focus. If you are accessing this article on another site, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this article can be viewed at https://www.equitiesfocus.com/2018/03/14/pra-health-sciences-prah-given-news-sentiment-rating-of-0-11.html.
PRA Health Sciences Company Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.